Kymera Therapeutics, Inc.
KYMRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeKymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by. With a market capitalization of $6.70B, it sits in mid-cap territory. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Market Cap
$6.70B
Beta
2.06
P/E (TTM)
—
P/E (Fwd)
-18.64
EPS (TTM)
$-3.58
EPS (Fwd)
$-4.37
ROE
-27.1%
ROA
-17.2%
Cash
$650.9M
Total Debt
$80.5M
Free CF
-$139.3M
52W Change
174.8%
Annual Financials
Cash vs Debt
With $650.9M in cash and $80.5M in debt, KYMR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$139.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -27.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $46.8M (2022) to $39.2M (2025), a 16% decline worth watching.
With a beta above 1.5, KYMR tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kymera Therapeutics, Inc.'s trajectory.